Skills, Research Focus, and Publications of Mitchell Higashi

Mitchell Higashi is a nationally recognized expert in health economics and outcomes research. His work covers real-world evidence, precision medicine, health technology assessment, and emerging applications of generative artificial intelligence in healthcare. Currently, Mitchell Higashi is the associate chief science officer, leading scientific and research initiatives at ISPOR to improve decision-making for health globally.

Throughout his career, Mr. Higashi has gained experience in assessing the economic value of pharmaceuticals, medical technologies, and healthcare delivery models. His professional focus includes health policy, rare diseases, regulatory decision-making, gene therapy, CAR-T therapies, pediatric conditions, and the integration of real-world data into clinical and reimbursement strategies.

Mr. Higashi’s research contributions include dozens of peer-reviewed publications addressing cost-effectiveness, pharmacogenomics, diagnostic imaging, simulation modeling, chronic disease burden, and advanced analytics in healthcare delivery. His work has appeared in leading journals such as JAMA, value in health, pharmacoeconomics, academic radiology, and clinical pharmacology & therapeutics.

Mr. Higashi has done some studies on how genetic variants affect the results of warfarin therapy. He has also evaluated the cost of treating cancer and chronic respiratory disease. Additionally, He has used simulation models to determine how healthcare systems can work better.

In addition to publishing extensively, Mr. Higashi has delivered presentations at major research summits, co-chaired international ISPOR conferences, and moderated large-scale expert panels featuring leaders from regulatory agencies, technology companies, and academic institutions on the future of AI in healthcare research.